Does the media refer more to GPCR or ELAN?

In the previous week, Elanco Animal Health had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for Elanco Animal Health and 3 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 0.66 beat Structure Therapeutics' score of 0.51 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GPCR or CORT?

In the previous week, Corcept Therapeutics had 25 more articles in the media than Structure Therapeutics. MarketBeat recorded 28 mentions for Corcept Therapeutics and 3 mentions for Structure Therapeutics. Corcept Therapeutics' average media sentiment score of 0.73 beat Structure Therapeutics' score of 0.51 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 9 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor GPCR or AXSM?

In the previous week, Axsome Therapeutics had 11 more articles in the media than Structure Therapeutics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 3 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Structure Therapeutics' score of 0.51 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend GPCR or RDY?

Structure Therapeutics currently has a consensus target price of $110.91, indicating a potential upside of 216.88%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.82 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to GPCR or RDY?

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 3 mentions for Structure Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 0.53 beat Structure Therapeutics' score of 0.51 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Structure Therapeutics (GPCR) Competitors

$35.00 -0.10 (-0.28%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$34.79 -0.21 (-0.61%)

As of 09/18/2026 07:55 PM Eastern

Compare

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

Should you buy Structure Therapeutics stock or one of its competitors? Structure Therapeutics's main competitors and comparable companies include Elanco Animal Health (ELAN), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Structure Therapeutics compare to Elanco Animal Health?

Structure Therapeutics (NASDAQ:GPCR) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Structure Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Elanco Animal Health	$4.72B	2.37	-$232M	-$0.41	N/A

Structure Therapeutics currently has a consensus target price of $110.91, suggesting a potential upside of 216.88%. Elanco Animal Health has a consensus target price of $29.09, suggesting a potential upside of 29.92%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 11 mentions for Elanco Animal Health and 3 mentions for Structure Therapeutics. Elanco Animal Health's average media sentiment score of 0.66 beat Structure Therapeutics' score of 0.51 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has a beta of -1.45, suggesting that its share price is 245% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Structure Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Elanco Animal Health	-3.96%	8.13%	3.99%

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Structure Therapeutics and Elanco Animal Health tied by winning 8 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Corcept Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Corcept Therapeutics has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Corcept Therapeutics	$830.81M	14.35	$99.65M	$0.42	262.60

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Corcept Therapeutics had 25 more articles in the media than Structure Therapeutics. MarketBeat recorded 28 mentions for Corcept Therapeutics and 3 mentions for Structure Therapeutics. Corcept Therapeutics' average media sentiment score of 0.73 beat Structure Therapeutics' score of 0.51 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	9 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Structure Therapeutics has a beta of -1.45, suggesting that its share price is 245% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

Corcept Therapeutics has a net margin of 6.52% compared to Structure Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Corcept Therapeutics	6.52%	8.26%	6.45%

Structure Therapeutics presently has a consensus target price of $110.91, suggesting a potential upside of 216.88%. Corcept Therapeutics has a consensus target price of $138.17, suggesting a potential upside of 25.28%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Structure Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Corcept Therapeutics beats Structure Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Axsome Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Structure Therapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Structure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Axsome Therapeutics	$638.50M	17.05	-$183.17M	-$3.75	N/A

In the previous week, Axsome Therapeutics had 11 more articles in the media than Structure Therapeutics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 3 mentions for Structure Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat Structure Therapeutics' score of 0.51 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has a beta of -1.45, indicating that its share price is 245% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 216.88%. Axsome Therapeutics has a consensus price target of $267.60, indicating a potential upside of 28.79%. Given Structure Therapeutics' higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Structure Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Structure Therapeutics' return on equity of -25.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

Summary

Structure Therapeutics beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Structure Therapeutics (NASDAQ:GPCR) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Structure Therapeutics currently has a consensus target price of $110.91, indicating a potential upside of 216.88%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Structure Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Structure Therapeutics has a beta of -1.45, meaning that its share price is 245% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for Dr. Reddy's Laboratories and 3 mentions for Structure Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 0.53 beat Structure Therapeutics' score of 0.51 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Dr. Reddy's Laboratories	$3.58B	2.84	$456M	$0.44	27.71

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Structure Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Summary

Dr. Reddy's Laboratories beats Structure Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Structure Therapeutics (NASDAQ:GPCR) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Structure Therapeutics has a beta of -1.45, meaning that its stock price is 245% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Structure Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Structure Therapeutics' return on equity of -25.56% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Structure Therapeutics presently has a consensus price target of $110.91, indicating a potential upside of 216.88%. Crinetics Pharmaceuticals has a consensus price target of $81.00, indicating a potential downside of 4.65%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Structure Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Structure Therapeutics has higher earnings, but lower revenue than Crinetics Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

In the previous week, Structure Therapeutics had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 3 mentions for Structure Therapeutics and 0 mentions for Crinetics Pharmaceuticals. Structure Therapeutics' average media sentiment score of 0.51 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Structure Therapeutics	Positive
Crinetics Pharmaceuticals	Neutral

Summary

Structure Therapeutics beats Crinetics Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Structure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GPCR vs. The Competition

Export

Metric	Structure Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.44B	$12.45B	$7.24B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-35.00	797.25	275.79	25.40
Price / Sales	N/A	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	1.40	10.53	10.46	6.33
Net Income	-$141.20M	$2.82B	$3.49B	$358.33M
7 Day Performance	-9.47%	1.69%	0.59%	1.12%
1 Month Performance	-35.34%	0.83%	-2.01%	-2.67%
1 Year Performance	48.43%	3.90%	18.09%	6.01%

Structure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GPCR Structure Therapeutics	2.5088 of 5 stars	$35.00 -0.3%	$110.91 +216.9%	+50.7%	$2.44B	N/A	N/A	281	Analyst Downgrade
ELAN Elanco Animal Health	4.3177 of 5 stars	$24.18 -1.3%	$29.09 +20.3%	+17.1%	$12.08B	$4.72B	N/A	9,400	Options Volume
CORT Corcept Therapeutics	4.1805 of 5 stars	$110.76 -0.8%	$138.17 +24.7%	+38.2%	$11.95B	$761.41M	263.29	300	Trending News Analyst Forecast Insider Trade Analyst Revision
AXSM Axsome Therapeutics	3.804 of 5 stars	$210.70 +1.9%	$267.60 +27.0%	+75.1%	$11.02B	$638.50M	N/A	380	News Coverage Analyst Forecast
RDY Dr. Reddy's Laboratories	1.671 of 5 stars	$11.82 -1.3%	N/A	-17.7%	$9.86B	$3.58B	26.85	27,527	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GPCR) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Elanco Animal Health?

Summary

How does Structure Therapeutics compare to Corcept Therapeutics?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Structure Therapeutics (GPCR) Competitors

GPCR vs. ELAN, CORT, AXSM, RDY, and CRNX

How does Structure Therapeutics compare to Elanco Animal Health?

Which has stronger valuation and earnings, GPCR or ELAN?

Do analysts prefer GPCR or ELAN?

Does the media refer more to GPCR or ELAN?

Which has more risk and volatility, GPCR or ELAN?

Is GPCR or ELAN more profitable?

Do insiders & institutionals have more ownership in GPCR or ELAN?

Summary

How does Structure Therapeutics compare to Corcept Therapeutics?

Which has better earnings & valuation, GPCR or CORT?

Do institutionals and insiders have more ownership in GPCR or CORT?

Does the media refer more to GPCR or CORT?

Which has more risk & volatility, GPCR or CORT?

Is GPCR or CORT more profitable?

Do analysts prefer GPCR or CORT?

Summary

How does Structure Therapeutics compare to Axsome Therapeutics?

Do institutionals & insiders believe in GPCR or AXSM?

Which has stronger earnings & valuation, GPCR or AXSM?

Does the media favor GPCR or AXSM?

Which has more volatility & risk, GPCR or AXSM?

Do analysts prefer GPCR or AXSM?

Is GPCR or AXSM more profitable?

Summary

How does Structure Therapeutics compare to Dr. Reddy's Laboratories?

Do institutionals and insiders believe in GPCR or RDY?

Do analysts recommend GPCR or RDY?

Which has more volatility & risk, GPCR or RDY?

Does the media refer more to GPCR or RDY?

Which has higher earnings & valuation, GPCR or RDY?

Is GPCR or RDY more profitable?

Summary

How does Structure Therapeutics compare to Crinetics Pharmaceuticals?

Which has more volatility and risk, GPCR or CRNX?

Do institutionals & insiders hold more shares of GPCR or CRNX?

Is GPCR or CRNX more profitable?

Do analysts recommend GPCR or CRNX?

Which has stronger earnings & valuation, GPCR or CRNX?

Does the media refer more to GPCR or CRNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GPCR vs. The Competition

Structure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools